MedTrace Logo

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen.

NCT03695835 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2020-07-22

No results posted yet for this study

Summary

A retrospective and prospective data collection study on 27 consecutive subjects with adenocarcinoma who were treated using the MyVaccx system by Dr. Gary Onik. Retrospective data were collected on the treatment with the immunotherapy system and prospective data will be collected as they are prospectively monitored through their normal standard of care for their original cancer.

Conditions

  • Adenocarcinoma

Interventions

DRUG

Immunotherapeutic Agents

Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

DEVICE

Ablation

Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents

Sponsors & Collaborators

  • Gary Onik MD

    lead INDIV

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-11
Primary Completion
2019-07-08
Completion
2020-06-17
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03695835 on ClinicalTrials.gov